Should I buy or sell Profound Medical stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PROF shares. View PROF analyst ratings or view top-rated stocks .

What is Profound Medical's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for Profound Medical's shares. Their PROF share price targets range from $11.00 to $20.00. On average, they anticipate the company's stock price to reach $14.58 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price. View analysts price targets for PROF or view top-rated stocks among Wall Street analysts .

How have PROF shares performed in 2024?

Profound Medical's stock was trading at $8.49 at the beginning of the year. Since then, PROF shares have decreased by 8.7% and is now trading at $7.75. View the best growth stocks for 2024 here .

When is Profound Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PROF earnings forecast .

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The business had revenue of $2.01 million for the quarter, compared to the consensus estimate of $1.90 million. Profound Medical had a negative net margin of 396.85% and a negative trailing twelve-month return on equity of 70.18%.

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free PROF Stock Alerts

$7.75

-0.09 (-1.15%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.30
▼
$7.82
50-Day Range: $7.81
▼
$9.20
52-Week Range: $7.11
▼
$15.49

Volume: 45,008 shs
Average Volume: 41,905 shs
Market Capitalization: $189.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.58

Get Profound Medical alerts:

Profound Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 88.2% Upside
$14.58 Price Target
Short Interest: Bearish
1.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.17) to ($1.04) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

666th out of 911 stocks

Surgical & Medical Instruments Industry

74th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Profound Medical has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.32% of the outstanding shares of Profound Medical have been sold short.
Short Interest Ratio / Days to Cover
Profound Medical has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Profound Medical has recently increased by 0.78%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Profound Medical does not currently pay a dividend.
Dividend Growth
Profound Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PROF.

2.3

News and Social Media Coverage

News Sentiment
Profound Medical has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Profound Medical this week, compared to 2 articles on an average week.
MarketBeat Follows
2 people have added Profound Medical to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Profound Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.52% of the stock of Profound Medical is held by insiders.
Percentage Held by Institutions
47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Profound Medical are expected to grow in the coming year, from ($1.17) to ($1.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Profound Medical is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Profound Medical is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Profound Medical has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Profound Medical Stock (NASDAQ:PROF)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PROF Stock News Headlines

April 19, 2024 | businesswire.com

Dr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth Company

April 18, 2024 | yahoo.com

'Keep him alive': Survivors, Memorial Medical Center salute organ donors

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 18, 2024 | msn.com

Medical Mall Wellness Center Set to Close | April 17, 2024 | News 19 at 6 p.m.

April 17, 2024 | finanznachrichten.de

Accuryn Medical Announces Leadership Transition

April 17, 2024 | msn.com

'Vibrant Spirit': Hit-And-Run Death Of Ridgefield Teen Leaves 'Profound Void' In 2 Communities

April 15, 2024 | americanbankingnews.com

Financial Survey: Profound Medical (NASDAQ:PROF) vs. Femasys (NASDAQ:FEMY)

April 14, 2024 | yahoo.com

The story of love and the challenges faced after a profound medical diagnosis

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 14, 2024 | markets.businessinsider.com

Introducing the Dr. Tyrone Malloy Scholarship for Medical Students: Nurturing Tomorrow's Leaders in Women's Health

April 14, 2024 | msn.com

Profound Autism Summit hosts caregivers in Mass. from across U.S. for 1st time

April 13, 2024 | seekingalpha.com

PRN:CA Profound Medical Corp.

April 9, 2024 | yahoo.com

'The Good Doctor' Star Bria Henderson Opens Up About a Profound Personal Loss

April 9, 2024 | msn.com

Cook County Clerk Karen Yarbrough dies after being hospitalized with "serious medical condition"

April 9, 2024 | globenewswire.com

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 6, 2024 | finance.yahoo.com

Shareholders in Profound Medical (TSE:PRN) are in the red if they invested three years ago

April 3, 2024 | msn.com

Personality has a profound influence on gene expression

April 3, 2024 | msn.com

The Enduring Legacy of Grey’s Anatomy Celebrating 21 Seasons of Medical Drama Excellence

April 2, 2024 | msn.com

Asheville Highway Animal Hospital preserves Black medical legacy in East Knoxville

April 1, 2024 | mirror.co.uk

EXCLUSIVE: 'My baby was brain damaged due to medical negligence - maternity services aren't fit for purpose'

April 1, 2024 | msn.com

UK teenagers losing ability to socialise offline, warns US’s top medical officer

April 1, 2024 | finance.yahoo.com

Ultimate Medical Academy Celebrates Commencement for Thousands of Healthcare Student Graduates

April 1, 2024 | mirror.co.uk

'My baby was brain damaged due to medical negligence - maternity services aren't fit for purpose'

April 1, 2024 | msn.com

Top 10 Medical Miracles of the Century (So Far)

March 29, 2024 | msn.com

Mayor Henry suffered medical emergency, was in hospice before he passed

March 29, 2024 | msn.com

The Strangest Medical Facts That Will Blow Your Mind

March 29, 2024 | msn.com

Family says Mayor Henry suffered medical emergency related to cancer diagnosis

See More Headlines

Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PROF
CUSIP: N/A
CIK: 1628808
Web: www.profoundmedical.com
Phone: (647) 476-1350
Fax: 64-7847-3739
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.58
High Stock Price Target: $20.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +91.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,570,000.00
Net Margins: -396.85%
Pretax Margin: -398.62%
Return on Equity: -70.18%
Return on Assets: -53.80%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 6.58
Quick Ratio: 5.48

Sales & Book Value

Annual Sales: $7.20 million
Price / Sales: 25.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.28 per share
Price / Book: 5.95

Miscellaneous

Outstanding Shares: 24,430,000
Free Float: 24,058,000
Market Cap: $185.91 million
Optionable: Optionable
Beta: 0.80

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Arun Swarup Menawat MBA (Age 69)
Ph.D., Chairman of the Board & CEO
Comp: $551.88k
Mr. Rashed Dewan (Age 56)
Chief Financial Officer
Comp: $250.37k
Dr. Mathieu Burtnyk (Age 42)
Chief Operating Officer
Comp: $246.1k
Mr. Hartmut Warnken (Age 51)
Chief Commercial Officer of Outside US
Comp: $224.93k
Mr. Abbey Goodman (Age 41)
Chief Commercial Officer of US
Comp: $353.75k
Mr. Stephen Kilmer
Investor Relations
Mr. Jacques F. Cornet (Age 68)
Senior VP & Product Leader Sonalleve
Mr. Matthew Sobczyk C.A.
CPA, Assistant Corporate Controller
Mr. Levant Tinaz
Software Developer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PROF Stock Analysis - Frequently Asked Questions

Should I buy or sell Profound Medical stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PROF shares.
View PROF analyst ratings or view top-rated stocks.
What is Profound Medical's stock price target for 2024?: 3 Wall Street analysts have issued 12 month price objectives for Profound Medical's shares. Their PROF share price targets range from $11.00 to $20.00. On average, they anticipate the company's stock price to reach $14.58 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts price targets for PROF or view top-rated stocks among Wall Street analysts.
How have PROF shares performed in 2024?: Profound Medical's stock was trading at $8.49 at the beginning of the year. Since then, PROF shares have decreased by 8.7% and is now trading at $7.75.
View the best growth stocks for 2024 here.
When is Profound Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PROF earnings forecast.

How were Profound Medical's earnings last quarter?: Profound Medical Corp. (NASDAQ:PROF) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The business had revenue of $2.01 million for the quarter, compared to the consensus estimate of $1.90 million. Profound Medical had a negative net margin of 396.85% and a negative trailing twelve-month return on equity of 70.18%.
How do I buy shares of Profound Medical?: Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Profound Medical (PROF) Stock Price, News & Analysis

Profound Medical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Profound Medical Stock (NASDAQ:PROF)

PROF Stock Price History

PROF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PROF Stock Analysis - Frequently Asked Questions

Overall MarketRank^™